Increased delivery of TAT across an endothelial monolayer following ischemic injury.
There is a great need for the development of vehicles capable of delivering therapeutic cargoes across the blood-brain barrier (BBB) and into brain cells. Cell-penetrating peptides (CPPs), such as TAT, present one such solution, and have been used successfully in vivo to deliver neuroprotective cargoes to the brain in models of stroke and seizure. However, a significant discrepancy exists in the literature, as other groups have not had the same success. One commonality between the successful studies is a compromised BBB. In this study, we hypothesized that ischemic injury increases the transport of TAT across an endothelial monolayer (comprised of bEnd.3 cells) in vitro and, consequently, increases TAT-mediated delivery into astrocytes on the other side. In the 24h following in vitro ischemia (oxygen-glucose deprivation), transendothelial electrical resistance (TEER) significantly decreased, indicating disruption of BBB integrity. Concomitantly, the transport of a green fluorescent protein (GFP)-TAT fusion protein significantly increased, and the transduction of GFP-TAT into astrocytes cultured on the other side of the endothelial monolayer significantly increased. These results explain why TAT-mediated delivery of therapeutic cargoes is successful in the ischemic brain but not in the uninjured brain with an intact BBB, highlighting the necessity for continued development of delivery vehicles. We conclude that although TAT may not be an efficient vehicle for trans-BBB delivery across an intact BBB, it may have utility in clinical situations when the BBB is disrupted.
Simon
Melissa J
MJ
Department of Biomedical Engineering, Columbia University, New York, NY 10027, United States.
Kang
Woo Hyeun
WH
Gao
Shan
S
Banta
Scott
S
Morrison
Barclay
B
D000818:Animals; D001253:Astrocytes / Q000378:metabolism; D001812:Blood-Brain Barrier / Q000378:metabolism* / Q000503:physiopathology; D002545:Brain Ischemia / Q000378:metabolism* / Q000503:physiopathology; D002460:Cell Line; D002478:Cells, Cultured; D017097:Electric Impedance; D004730:Endothelium, Vascular / Q000378:metabolism* / Q000503:physiopathology; D051379:Mice; D014677:Pharmaceutical Vehicles; D051381:Rats; D017207:Rats, Sprague-Dawley; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000378:metabolism*
D014677:Pharmaceutical Vehicles; D054322:tat Gene Products, Human Immunodeficiency Virus